drugset / Trial / NCT02892149

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149 ↗

Phase 3 Completed 3554 enrolled Akebia Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)

Timeline

Start
2016-08
Primary completion
2020-01-16
Completion
2020-03-30

Outcome

Met primary endpoint

paper Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. PMID 33913638 ↗

release “In INNO2VATE's Conversion study of dialysis patients (n=3,554): Primary Efficacy Endpoint Result: Vadadustat was non-inferior to darbepoetin alfa.” akebia.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic — Subcutaneous
Subject Vadadustat Small molecule — Oral